DMAA

#3442
Drugs Made In America Acquisition Corp. - Ordinary Shares
10.7 5 USD
0.00%
Market Price
Sektor: Finanzen
Basis: USD
Gewinnwährung: USD
Tagesspanne
10.75
10.75
Jahresspanne
10.40
10.76
Tagesänderung
-0.09%
Monatliche Änderung
+0.47%
6 month change
+2.73%
Jahresänderung
+2.97%
Vorheriger Schlusskurs
10.7 6
Open
10.7 5
Tief
10.7 5
Hoch
10.7 5
Volumen
1
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Drugs Made In America Acquisition Corp. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Drugs Made In America Acquisition Corp. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Drugs Made In America Acquisition Corp. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Drugs Made In America Acquisition Corp. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Drugs Made In America Acquisition Corp. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Drugs Made In America Acquisition Corp. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Drugs Made In America Acquisition Corp. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Drugs Made In America Acquisition Corp. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Drugs Made In America Acquisition Corp. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Drugs Made In America Acquisition Corp. current report, Q1 FY2026
8-K

Drugs Made In America Acquisition Corp. current report, Q4 FY2025

Full document

Business Context and Reporting Period

This Form 8-K filing by Drugs Made In America Acquisition Corp. (DMAA) reports corporate governance changes effective October 8, 2025, and November 17, 2025. The company is a Cayman Islands-based special purpose acquisition company (SPAC) with securities trading on The Nasdaq Stock Market LLC under the symbols DMAAU, DMAA, and DMAAR.

Key Financial Metrics

The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive personnel changes and associated compensation arrangements.

Material Changes

  • Resignation: Glenn Worman resigned as Chief Financial Officer (CFO) and principal financial and accounting officer effective October 8, 2025. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
  • Appointment: Saleem Elmasri was appointed as the new CFO and principal financial and accounting officer, effective November 17, 2025.
  • Compensation Structure: Services are provided via Titan Advisory Services LLC under a Master Services Agreement. The Company will pay $42,000 annually ($3,500 per month). Additionally, 100,000 ordinary shares will be granted or transferred to Mr. Elmasri upon engagement.

Outlook, Risks, and Management Commentary

Management commentary is limited to the biographical background of the new CFO, Mr. Elmasri, who holds a CPA and has 20 years of experience, including roles at PwC and various boutique advisory firms. No specific business outlook, risk factors, or contingencies related to the company's acquisition strategy are disclosed in this filing. Standard indemnity, letter, and registration rights agreements are expected to be executed.

Investor Verification Checklist

  • Verify the effective date of the new CFO's appointment (November 17, 2025) against the resignation date of the prior CFO (October 8, 2025) to assess the duration of the interim period.
  • Confirm the source of the 100,000 shares granted to the new CFO (whether issued by the company or transferred from the CEO's holdings).
  • Review the Master Services Agreement with Titan Advisory Services LLC for any additional terms not summarized in the 8-K.
  • Check for any subsequent filings regarding the status of the company's trust account or search for a target acquisition during the interim leadership period.